Altos Labs

Altos Labs is a biotechnology company developing medicines through cellular rejuvenation: restoring cell health and resilience with the goal of reversing disease, injury and disabilities. Its research connects experimental biology with machine learning to understand how health operates across cells and organs. The company is developing multi-scale generative models using internally generated biological data alongside external datasets, bringing computational scientists and experimental biologists together to investigate potential treatments.

Launched in 2022, Altos was founded by Hal Barron, Rick Klausner and Hans Bishop. Barron serves as CEO, Klausner as Chief Scientific Advisor and Bishop as President. Its Institute of Computation, directed by Hana El-Samad, develops models of biological resilience at the cell, organ and organism levels. Teams build data and computation platforms for discovering, designing and understanding rejuvenation and reprogramming interventions.

Altos is privately held, with operations in the San Francisco Bay Area, San Diego and Cambridge, UK. Its organizational model combines academic freedom to investigate fundamental biology with drug development focused on patients: the Institutes of Science pursue discovery, while the Institute of Medicine translates knowledge of cell health and programming into potential medicines. At its 2022 launch, the company reported $3 billion in committed funding.